Aspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome: a 10-year retrospective study

Damien Contou1,2, Matthieu Dorison1, Jérémy Rosman1, Frédéric Schlemmer3, Aude Gibelin1, Françoise Foulet4, Françoise Botterel4, Guillaume Carteaux1,2, Keyvan Razazi1,2, Christian Brun-Buisson1,2, Armand Mekontso Dessap1,2 and Nicolas de Prost1,2*

Abstract
Background: The detection of Aspergillus spp. in endotracheal aspirate cultures of mechanically ventilated patients may reflect either colonization or infection. However, little is known about the prevalence and the impact on outcome of respiratory tract sample positive for Aspergillus during the acute respiratory distress syndrome (ARDS).

Methods: We conducted a monocentric, retrospective study over a 10-year period (January 2006–December 2015) in the ICU of a university hospital. All consecutive adult patients with ARDS were included, and the diagnosis of invasive pulmonary aspergillosis was assessed using a previously validated algorithm.

Results: In total, 423 ARDS patients were included with 35 patients [8.3%, 95% CI (5.4–10.6)] having at least one respiratory tract sample positive for Aspergillus (Aspergillus+ patients) after a median delay of 3 days (1–11) following ICU admission. Comorbidities did not differ between Aspergillus+ and Aspergillus− patients except for more frequent immunosuppression in Aspergillus+ patients (40 vs. 22%; p = 0.02). There was no difference between Aspergillus− and Aspergillus+ patients regarding in-ICU mortality, ventilator-free days at day 28, and incidence of ventilator-associated pneumonia, but need for renal replacement therapy was higher in Aspergillus+ patients than in others (49 vs. 27%; p = 0.01). Seventeen [4.0%, 95% CI (2.1–5.9)] patients had putative/proven aspergillosis. After adjusting on covariates associated with ICU mortality, putative/proven aspergillosis was associated with in-ICU mortality [aOR = 9.58 (1.97–46.52); p = 0.005], while Aspergillus colonization was not [aOR = 0.64 (0.21–1.99); p = 0.44].

Conclusions: Eight percent of ARDS patients had Aspergillus spp.-positive respiratory tract cultures. These had a higher risk of mortality only when categorized as having putative or proven invasive pulmonary aspergillosis.

Keywords: Aspergillus, Invasive pulmonary aspergillosis, Acute respiratory distress syndrome, Immunosuppression

Background
Invasive pulmonary aspergillosis (IPA) has been reported chiefly in immunocompromised patients with prolonged neutropenia, organ and allogeneic stem cell transplantation, prolonged corticosteroids use or severe inherited immunodeficiency [1]. However, in the past decade, definite cases of IPA have also been reported in intensive care unit (ICU) patients having none of the previously defined host risk factors for IPA [2], but other associated illnesses including advanced cirrhosis [3, 4], H1N1 influenza infection [5] or chronic obstructive pulmonary disease (COPD) [4–7]. In one study, the prevalence of IPA
reached 6% in a cohort of patients without malignancy hospitalized in a medical ICU [4]. Endotracheal aspirate cultures growing *Aspergillus* spp. have been recorded in 1–2% of mechanically ventilated ICU patients having no predisposing factors and may reflect either colonization or infection [8–11]. A recent clinical algorithm developed by Blot et al. demonstrated favorable operating characteristics to discriminate *Aspergillus* respiratory tract colonization from IPA in ICU patients, whereas the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria failed to adequately categorize patients in the absence of conventional risk factors [1].

The acute respiratory distress syndrome (ARDS) [12] occurs in about 10% of ICU patients and is associated with a high mortality of 35% [13]. Respiratory tract colonization was shown to be more frequent in ARDS than in other critically ill patients [14]. An autopsy study of 64 patients with ARDS revealed that 8 of them (13%) had died with pulmonary lesions of IPA [15]. However, the burden of IPA during ARDS has been poorly studied and little is known on the prevalence of *Aspergillus* respiratory tract colonization and IPA during ARDS, as well as on the prognosis of IPA in this setting. In this monocenter retrospective study we aimed at: (1) assessing the prevalence, (2) reporting the clinical characteristics, and (3) evaluating the impact on outcome of *Aspergillus*-positive lower respiratory tract specimen in ARDS patients.

**Methods**

We conducted a monocenter retrospective study in the 24-bed medical ICU of a tertiary referral center (Henri Mondor Hospital, Créteil, France). All consecutive adult (>18 years) patients admitted in the ICU for ARDS according to the Berlin definition criteria (within 48 h of admission) and receiving invasive mechanical ventilation over a 10-year period (January 2006 to December 2015) were included [12]. Exclusion criteria were as follows: previously known lung interstitial disease or tumor infiltration, chronic respiratory failure requiring long-term oxygen therapy, pure cardiogenic pulmonary edema, mild ARDS treated with noninvasive ventilation only, proven or suspected invasive pulmonary aspergillosis under antifungal therapy upon ARDS diagnosis and patients for whom no endobronchial sampling had been obtained.

All respiratory tract samples (plugged telescoping catheter, tracheal aspirate or bronchoalveolar fluid) performed for microbiological examination were analyzed. Galactomannan antigen (GM) detection in plasma and in bronchoalveolar lavage (BAL) fluid was performed at the discretion of the managing physician. An optical density ratio of 0.5 or greater for GM in serum and of 1.0 or greater for BAL fluid was considered positive. Chest CT scan and cerebral or facial scan were not routinely performed.

**Definition of infection and categorization of patients**

Patients were categorized into two groups: those with one or more respiratory tract sample positive in culture for *Aspergillus* spp. (*Aspergillus* + patients) during the ICU stay and those without such positive sample (*Aspergillus* − patients). The former group was further split into three categories depending on the probability of IPA according to the clinical algorithm proposed by Blot et al. [16]: (A) proven IPA (microscopic analysis on sterile material: histopathologic, cytopathologic or direct microscopic examination of a specimen obtained by needle aspiration or sterile biopsy in which hyphae are seen accompanied by evidence of associated tissue damage; isolation of *Aspergillus* from culture of a specimen obtained by lung biopsy); (B) putative IPA in case of (1) *Aspergillus*-positive lower respiratory tract specimen culture (entry criterion) with (2) compatible signs and symptoms (one of the following: fever refractory to at least 3 days of appropriate antibiotic therapy, recrudescence fever after a period of defervescent of at least 48 h while still on antibiotics and without other apparent cause, pleuritic chest pain, pleuritic rub, dyspnea, hemoptysis, worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory support) and (3) abnormal medical imaging by portable chest X-ray or CT scan of the lungs, and either (4a) a host risk factor (one of the following conditions: neutropenia (absolute neutrophil count <500 G/L) preceding or at the time of ICU admission, underlying hematological or oncological malignancy treated with cytotoxic agents, glucocorticoid treatment (prednisone equivalent >20 mg/day), congenital or acquired immunodeficiency) or (4b) a semiquantitative *Aspergillus*-positive culture of BAL fluid (+ or ++), without bacterial growth together with a positive cytological smear showing branching hyphae or (C) *Aspergillus* respiratory tract colonization when ≥1 criterion necessary for a diagnosis of putative IPA was not met (Tables 1, 2).

**Collection of data and definitions**

Demographics and clinical characteristics upon ICU admission and during ICU stay were abstracted from the medical charts of all patients. Immunosuppression was defined by one of the following conditions: neutropenia (absolute neutrophil count <500 G/L) preceding or at the time of ICU admission, underlying hematological or oncological malignancy treated with cytotoxic agents, glucocorticoid treatment (prednisone equivalent >20 mg/
day for more than 4 weeks), congenital (e.g., chronic granulomatous disease, hyper-IgE syndrome [17]) or acquired (e.g., AIDS [18]) immunodeficiency. Patient initial severity was assessed using the Simplified Acute Physiology Score II (SAPS II) [19] and Logistic Organ Dysfunction (LOD) [20] scores. ARDS was categorized as mild, moderate or severe according to the lowest PaO2/FiO2 ratio obtained within 48 h of ICU admission [12]. Shock was defined as need for vasopressor (epinephrine or norepinephrine) at a dose higher than 1 mg/h for more than 2 h. Outcome variables included the use of adjuvant therapies for ARDS (i.e., neuromuscular blocking agents, nitric oxide inhalation, prone positioning or venovenous extracorporeal membrane oxygenation), the need for renal replacement therapy or vasopressors, the administration of corticosteroids, the number of ventilator-free days at day 28, the duration of ICU stay, the incidence of ventilator-associated pneumonia and in-ICU mortality.

All chest CT scans performed in Aspergillus+ patients were reviewed by two pulmonologists (FS and NDP) blinded to the final Aspergillus classification and outcome. Elementary lesions including alveolar consolidation, lung nodules, ground-glass opacities, halo sign, cavitation and pleural effusion were recorded.

### Patient’s management

ARDS patients received mechanical ventilation using a standardized protective ventilation strategy [21, 22]. Tracheal suction was performed using a closed system. Other treatments including neuromuscular blocking agents [23], nitric oxide inhalation, prone positioning [24] and venovenous extracorporeal membrane oxygenation were administered depending on the severity of ARDS [25].

Antifungal therapy (voriconazole, caspofungin or liposomal amphotericin B) was administered at the

### Table 1 Demographics and clinical characteristics upon ICU admission of ARDS patients with (Aspergillus+) or without (Aspergillus−) one or more respiratory tract sample positive for Aspergillus spp.

|                          | All (n = 423) | Aspergillus− (n = 388) | Aspergillus+ (n = 35) | p value |
|--------------------------|--------------|------------------------|----------------------|---------|
| Age (years)              | 62 (50–72)   | 62 (50–72)             | 62 (49–72)           | 0.82    |
| Gender (male)            | 282 (67)     | 258 (66)               | 24 (69)              | 0.85    |
| Previously known aspergillosis | 8 (2)  | 7 (2)       | 1 (3)                | 0.50    |
| Immunosuppression        | 100 (24)     | 86 (22)                | 14 (40)              | 0.023   |
| COPD                     | 48 (11)      | 44 (11)                | 4 (11)               | >0.99   |
| Inhaled steroids         | 16 (4)       | 15 (4)                 | 1 (3)                | >0.99   |
| Liver cirrhosis          | 44 (10)      | 42 (11)                | 2 (6)                | 0.56    |
| Chronic renal failure    | 16 (4)       | 15 (4)                 | 1 (3)                | >0.99   |
| Diabetes mellitus        | 85 (20)      | 79 (20)                | 6 (17)               | 0.83    |
| SAPS II                  | 53 (37–69)   | 53 (38–70)             | 51 (34–68)           | 0.65    |
| LODS                     | 8 (6–12)     | 8 (6–12)               | 7 (5–11)             | 0.26    |
| Main ARDS risk factors   |              |                        |                      |         |
| Pulmonary infection      | 202 (48)     | 173 (45)               | 29 (83)              | <0.0001 |
| Aspiration               | 154 (36)     | 147 (38)               | 7 (20)               | 0.043   |
| Non-pulmonary sepsis     | 87 (21)      | 84 (22)                | 3 (9)                | 0.080   |
| Drug overdose            | 12 (3)       | 11 (3)                 | 1 (3)                | >0.99   |
| Delay first respiratory symptom—admission, days | 2 (0–5) | 2 (0–5) | 2 (0–8) | 0.41 |
| Temperature > 38.3 °C    | 220 (52)     | 199 (51)               | 21 (60)              | 0.38    |
| Noninvasive ventilation  | 69 (16)      | 65 (17)                | 4 (11)               | 0.63    |
| Berlin classification    |              |                        |                      | 0.38    |
| Mild                     | 113 (27)     | 104 (27)               | 9 (26)               |         |
| Moderate                 | 162 (38)     | 144 (37)               | 18 (51)              |         |
| Severe                   | 148 (35)     | 140 (36)               | 8 (23)               |         |
| PaO2/FiO2 ratio (mm Hg)  | 106 (77–163) | 106 (78–162)           | 114 (76–173)         | 0.84    |
| Shock                    | 325 (77)     | 297 (76)               | 28 (80)              | 0.83    |
| Serum creatinine (µmol/L)| 120 (82–180) | 120 (82–177)           | 128 (82–207)         | 0.76    |

ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease; continuous variables are shown as median (interquartile range 25–75); categorical variables are shown as n (%).
discretion of the managing physician and not initiated on the sole basis of a positive GM in serum or in BAL fluid.

### Statistical analysis
Continuous variables are reported as median [25th–75th percentiles] or mean ± standard deviation (SD) and compared as appropriate. Categorical variables are reported as numbers and percentages [95 % confidence interval (95 % CI)] and compared as appropriate. There was no imputation for missing data, except for data missing from comorbidities, which were then considered as absent. Factors associated with ICU mortality were determined by univariable and multivariable backward logistic regression analyses. Independent variables with a \( p \) value <0.10 in univariable analysis were entered into the multivariable model, with backward elimination of variables displaying a \( p \) value greater than 0.05. Interactions between variables were assessed using the Mantel–Haenszel test. Analyses were conducted using the SPSS Base 21.0 statistical software package (SPSS Inc., Chicago, IL).

### Results
#### Prevalence of \textit{Aspergillus}+ respiratory tract samples during ARDS
Over the 10-year study period, 423 patients were admitted for ARDS, of whom 35 [8.3 %, 95 % CI (5.4–10.6)] had at least one respiratory tract sample positive for \textit{Aspergillus} spp. (Aspergillus+ patients) (Fig. 1; Table 1). Among 17 (49 %) immunocompromised Aspergillus+ patients, one had proven IPA, 11 had putative IPA, and 5 were categorized as having respiratory tract colonization. Conversely, among 18 (51 %) non-immunocompromised Aspergillus+ patients, 5 had putative IPA and 13 had colonization (Fig. 1; Table 2). The overall prevalence of proven/putative aspergillosis was 4.0 % [95 % CI (2.1–5.9)].

#### Presentation of ARDS patients with \textit{Aspergillus}-positive respiratory tract samples
Comorbidities did not differ between Aspergillus+ and Aspergillus− patients except for more frequent
immunosuppression in the former group (Table 1). The two groups did not differ regarding clinical presentation and severity of illness upon ICU admission, as assessed by SAPS II, LODS and ARDS severity. Regarding the main ARDS risk factors retrieved, infective pneumonia was significantly more frequent (while aspiration pneumonia was less frequent) in Aspergillus + patients than in others (Table 1).

Among the 35 patients of the Aspergillus + group, 27 (77 %) had a GM measurement performed in both plasma and BAL fluid. Plasma GM measurements were not significantly different between patients with proven/putative IPA and those with Aspergillus spp. colonization (7/15, 47 % vs. 2/12, 17 %, p = 0.22). In contrast, when measured in BAL fluid, GM was more frequently positive in patients with proven/putative IPA than in those with Aspergillus colonization (8/15, 53 % vs. 0/12, 0 %, p = 0.003) (Table 3).

Chest CT scans were obtained in 60 % (n = 21/35) of patients of the Aspergillus + group during ICU stay (Table 4; Fig. 2) and displayed no significant difference between patients categorized as having proven/putative aspergillosis (n = 13/21) and those with Aspergillus colonization (n = 8/21). Of note, while lung nodules were observed in 67 % of cases, other chest CT scan patterns suggestive of IPA, including lung cavitation and halo sign, were detected in only 14 % of cases. Alveolar consolidations, consistent with the underlying ARDS, were present in 90 % of cases.

Management and outcome of ARDS patients with Aspergillus-positive respiratory tract samples

The median number of collected samples was 3 (2–7) per patient, and the median delay between ICU admission and the first respiratory tract sample positive for Aspergillus spp. was 3 days (1–11) (Table 5). There were no differences between Aspergillus− and Aspergillus+ patients regarding duration of ICU stay, in-ICU mortality, number of ventilator-free days at day 28 and incidence of ventilator-acquired pneumonia and of shock. In contrast, the need for renal replacement therapy was almost twice as high in Aspergillus+ patients than in others (Table 5).

Within the Aspergillus+ group, fifteen patients received an antifungal treatment during ICU stay (voriconazole, n = 12; liposomal amphotericin B, n = 3; caspofungin, n = 2; combination therapy, n = 3), including the sole
patient with proven IPA, 10 over 16 patients with putative IPA and 4 over 18 patients with Aspergillus respiratory tract colonization.

The association between Aspergillus status, as categorized with the Blot et al. algorithm, and in-ICU mortality was assessed by logistic regression analysis. Both in univariable analysis \([\text{OR} = 7.98 \ (1.80–35.36), \ p = 0.006]\) and after adjusting for covariates significantly associated with ICU mortality, putative/proven IPA was strongly associated with in-ICU mortality \([\text{aOR} = 9.58 \ (1.97–46.52), \ p = 0.005]\), while Aspergillus colonization was not \([\text{aOR} = 0.64 \ (0.21–1.99), \ p = 0.44]\) (Table 6). Of note, within the putative/proven IPA subgroup \((n = 17)\), 10/12 immunocompromised and 5/5 non-immunocompromised patients died in the ICU.

**Discussion**

We herein report Aspergillus-positive lower respiratory tract specimen culture in an 8 % prevalence of patients with ARDS, half of whom had putative or proven IPA. Immunosuppression and pneumonia were more frequent among patients having at least one positive sample for Aspergillus. Immunocompromised ARDS patients were more frequently categorized as having putative or proven IPA, while non-immunocompromised patients were more likely categorized as having Aspergillus respiratory tract colonization. Importantly, patients with one or more positive respiratory tract sample for Aspergillus had a worse outcome than others only when categorized as having putative/proven IPA according to the Blot algorithm.

The current series is, to the best of our knowledge, the largest one to focus on Aspergillus-positive respiratory tract samples in ARDS patients. The 8 % prevalence of patients having at least one positive sample for Aspergillus, in our population with ARDS, is significantly higher than the 1 % rate prospectively reported by Bassetti et al. in unselected mechanically ventilated patients, suggesting ARDS is a risk factor for Aspergillus respiratory colonization and/or infection [14]. Four percent of our ARDS patients \((n = 17/423)\) were eventually classified as having proven or putative IPA, which is less than the 13 % prevalence of proven IPA that was previously reported in an autopsy study of 64 patients with ARDS [15], likely due to differences in case-mix and methods between this study and ours. Such figures are consistent with the fact that the Blot et al. algorithm was previously shown to have 61 % specificity and positive predictive value and 92 % sensitivity and negative predictive value, implying that its ability to exclude IPA might be better than in diagnosing it [16, 26]. Strikingly, the median delay between the first respiratory sample positive for Aspergillus spp. and mechanical ventilation initiation was 3 days, consistent with a previous study in mechanically ventilated patients with ARDS having at least one positive sample for Aspergillus.

**Table 3 Serum and bronchoalveolar lavage fluid galactomannan antigen according to the probability of invasive pulmonary aspergillosis (Blot et al. algorithm [16])**

|                        | All \((n = 27)\) | Proven/putative aspergillosis \((n = 15)\) | Aspergillus colonization \((n = 12)\) | \(p\) value\(^a\) |
|------------------------|-----------------|-------------------------------------------|--------------------------------------|-----------------|
| Positive serum galactomannan | 9 (33)          | 7 (47)                                    | 2 (17)                               | 0.22            |
| Positive BAL fluid galactomannan | 8 (30)          | 8 (53)                                    | 0 (0)                                | 0.003           |

\(^a\) \(p\) value comes from the Fisher exact test; an optical density (OD) ratio of 0.5 or greater for galactomannan antigen in serum and 1.0 for BAL fluid was considered positive

**Table 4 Chest CT scan patterns in patients \((n = 21)\) categorized as having proven/putative invasive pulmonary aspergillosis or Aspergillus colonization, according to the Blot algorithm [16]**

|                        | All \((n = 21)\) | Proven/putative aspergillosis \((n = 13)\) | Aspergillus colonization \((n = 8)\) | \(p\) value\(^a\) |
|------------------------|-----------------|-------------------------------------------|--------------------------------------|-----------------|
| Pulmonary infiltrates  | 21 (100)        | 13 (100)                                   | 8 (100)                              | >0.99           |
| Alveolar consolidation | 19 (90)         | 11 (85)                                    | 8 (100)                              | 0.11            |
| Lung nodules           | 15 (71)         | 8 (61)                                     | 7 (87)                               | 0.33            |
| Ground-glass opacities | 14 (67)         | 10 (77)                                    | 4 (50)                               | 0.34            |
| Cavitation             | 3 (14)          | 1 (8)                                      | 2 (25)                               | 0.53            |
| Halo sign              | 3 (14)          | 2 (15)                                     | 1 (12)                               | >0.99           |
| Pleural effusion       | 12 (57)         | 8 (61)                                     | 4 (50)                               | 0.67            |

\(^a\) \(p\) value comes from the Fisher exact test; categorical variables are shown as \(n\) (%)

---

Contou et al. Ann. Intensive Care (2016) 6:52
non-ARDS patients [11], suggesting that respiratory tract colonization by *Aspergillus* spores had occurred prior to ARDS onset. The combination of ARDS-associated alveolar damage and associated local immune dysregulation [27], together with sepsis-induced immunosuppression [28], might, through alterations in innate immunity and antigen presentation processes [29], account for the development of IPA in previously colonized patients. Other previously described conditions at risk of IPA in critically ill non-immunosuppressed patients include COPD, present in only 11% of our Aspergillus+ group, as compared to 31% in a large series and, to a lesser extent, cirrhosis and corticosteroids, observed in less than 10% of cases [6]. Surprisingly, however, corticosteroid administration was not associated with mortality in a recent series of mechanically ventilated patients with proven or putative Aspergillosis [6]. Although we found a trend toward more high-dose steroids administration in the
Table 5 Management and outcomes of ARDS patients with (Aspergillus\textsuperscript{+}) or without (Aspergillus\textsuperscript{−}) one or more respiratory tract sample positive for Aspergillus spp.

| Microbiological examinations | All (n = 423) | Aspergillus\textsuperscript{−} (n = 388) | Aspergillus\textsuperscript{+} (n = 35) | p value |
|------------------------------|--------------|-----------------------------------|---------------------------------|--------|
| Number of endobronchial samples | 4.0 (2.0–7.0) | 3.5 (2.0–7.0) | 4.5 (2.7–9.2) | 0.019 |
| Including BAL | 211 (48) | 181 (45) | 30 (86) | <0.0001 |
| Duration of ICU stay (days) | 12 (6–22) | 12 (6–22) | 14 (7–35) | 0.14 |
| Ventilator-free days at day 28 (days) | 0 (0–17) | 0 (0–22) | 0 (0–16) | 0.19 |
| Ventilator-acquired pneumonia | 146 (35) | 135 (35) | 11 (31) | 0.85 |
| Treatment | | | | |
| Prone position | 169 (40) | 153 (40) | 16 (46) | 0.48 |
| Nitric oxide inhalation | 117 (28) | 108 (28) | 9 (26) | 0.85 |
| Paralyzing agents | 380 (92) | 348 (92) | 32 (91) | >0.99 |
| ECMO | 21 (5) | 18 (5) | 3 (9) | 0.40 |
| Shock | 350 (83) | 321 (83) | 29 (83) | >0.99 |
| Renal replacement therapy | 122 (29) | 105 (27) | 17 (49) | 0.011 |
| Corticosteroids | | | | |
| "Stress-dose" steroids \textsuperscript{a} | 144 (34) | 134 (34) | 10 (29) | 0.58 |
| "High-dose" steroids \textsuperscript{b} | 96 (23) | 84 (22) | 12 (34) | 0.094 |
| In-ICU mortality | 209 (50) | 188 (48) | 21 (60) | 0.22 |

ECMO extracorporeal membrane oxygenation, BAL bronchoalveolar lavage

\textsuperscript{a} Hydrocortisone 200 mg/day

\textsuperscript{b} Prednisone equivalent >1 mg/kg/day; continuous variables are shown as median (interquartile range 25–75); categorical variables are shown as n (%)

Table 6 Univariable and multivariable logistic regression analyses of factors associated with ICU mortality in ARDS patients

| | n | Death n (%) | Univariable analysis | Multivariable analysis |
|---|---|-----------|---------------------|-----------------------|
| | | | OR (95 % CI) | p | aOR (95 % CI) | p |
| Age (years) | – | – | 1.02 (1.01–1.03) | <0.0001 | 1.02 (1.00–1.03) | 0.029 |
| Year of inclusion | – | – | 0.89 (0.82–0.95) | <0.001 | – | – |
| Liver cirrhosis | | | | | | |
| Yes | 44 | 31 (70.5) | 2.69 (1.37–5.31) | 0.004 | 2.62 (1.24–5.54) | 0.012 |
| No | 379 | 178 (47.0) | 1 | | 1 |
| Immunosuppression | | | | | | |
| Yes | 100 | 58 (58.0) | 1.57 (1.00–2.47) | 0.050 | 1.83 (1.08–3.11) | 0.024 |
| No | 323 | 151 (46.7) | 1 | | 1 |
| PaO\_2/FiO\_2 ratio (mmHg) | – | – | 0.99 (0.99–0.99) | <0.0001 | 0.99 (0.99–0.99) | <0.0001 |
| SAPS II | – | – | 1.03 (1.02–1.04) | <0.0001 | 1.02 (1.00–1.03) | 0.018 |
| LODS | – | – | 1.19 (1.13–1.25) | <0.0001 | 1.12 (1.05–1.20) | <0.001 |
| Antifungal treatment \textsuperscript{a} | | | | | | |
| Yes | 17 | 12 (70.6) | 2.55 (0.88–7.36) | 0.084 | – | – |
| No | 406 | 197 (48.5) | 1 | | 1 |
| Blot et al. algorithm\textsuperscript{[16]} | | | | | | |
| No Aspergillus spp. colonization | 388 | 188 (48.5) | 1 | – | 1 | – |
| Aspergillus spp. colonization | 18 | 6 (33.3) | 0.53 (0.20–1.45) | 0.22 | 0.64 (0.21–1.99) | 0.44 |
| Putative or proven IPA | 17 | 15 (88.2) | 7.98 (1.80–35.36) | 0.006 | 9.58 (1.97–46.52) | 0.005 |

\textsuperscript{a} IPA invasive pulmonary aspergillosis

\* As prescribed for a suspicion of invasive pulmonary aspergillosis; the Hosmer–Lemeshow goodness of fit test showed good calibration of the model (p = 0.28); the area under the curve of the model is 0.78 (0.73–0.82); OR (95 % CI), odds ratio (95 % confidence interval); aOR, adjusted odds ratio
Aspergillus-positive group, their relationship with subsequent IPA and death could not be assessed in our study due to its limited statistical power.

The recent clinical algorithm proposed by Blot et al. for discriminating between ICU patients with Aspergillus respiratory tract colonization and those with IPA, allows for categorizing non-immunocompromised patients as having putative IPA, provided semiquantitative culture of BAL fluid is positive for Aspergillus, together with a positive cytological smear showing branching hyphae [16]. This criterion (4b) becomes indeed crucial in non-immunocompromised ARDS patients who all meet, by definition, the radiological criterion of the Blot algorithm (criterion 3), while both the relevance and reproducibility of several of the clinical criteria (e.g., dyspnea, pleuritic chest pain, pleuritic rub) can be questioned in critically ill mechanically ventilated patients. Nevertheless, and as expected, immunosuppression was strongly associated with proven/putative IPA in our series; however, it is noteworthy that non-immunocompromised patients accounted for one-third of patients classified as having probable infection, all of whom (n = 5/5) eventually died, suggesting putative IPA portends a dismal prognosis even in non-immunocompromised patients.

Although the purpose of our study was not to evaluate the performance value of GM antigen measurement, our results suggest that its detection is more efficient in BAL fluid than in plasma to discriminate between proven/putative IPA and Aspergillus colonization, in line with a previous prospective study conducted in non-ARDS critically ill patients [30]. In the context of ARDS patients with a positive culture for Aspergillus, a positive GM test in BAL fluid may be a helpful tool to reinforce the diagnostic suspicion of IPA and may thus incite clinicians to start antifungal therapy.

While the number of chest CT scans available in the current study was limited, our results suggest that, in the particular context of ARDS, its diagnostic yield to discriminate between putative aspergillosis and Aspergillus colonization is limited, most patients exhibiting non-specific findings such as alveolar consolidations.

In our series, the overall positivity of one or more respiratory sample for Aspergillus was not significantly associated with higher in-ICU mortality. Still, the risk of in-ICU mortality was significantly higher in ARDS patients with proven/putative IPA, as opposed to those with Aspergillus colonization, and as compared to those having no positive respiratory tract culture for Aspergillus, even after adjusting on significantly associated covariables. The benefit/risk ratio of antifungal therapy has not been assessed in ICU patients when categorized as having proven/putative IPA according to the recently proposed algorithm [16]. Our findings of a higher in-ICU mortality among a cohort of ARDS patients suggest that the initiation of such treatment should be considered in this specific subgroup, including non-immunocompromised patients, who also exhibited a strikingly high ICU mortality (n = 5/5 died). Of note, a previous observational study in critically ill COPD patients having putative IPA reported no improvement in ICU and long-term mortality in patients receiving antifungal treatment as compared to others, suggesting the severity of the underlying diseases was a key prognostic factor [7]. Strikingly, in the current series, six patients of the putative IPA subgroup (n = 16) did not receive an antifungal treatment, reflecting the fact that the criteria on which such treatment should be initiated in patients having Aspergillus spp.-positive respiratory tract samples are not standardized yet.

Our study has a number of limitations. First, due to its monocentric design, our results may not be applicable to other centers, thereby limiting their generalizability, since risk exposure to Aspergillus, prevalence of colonization and subsequent IPA may vary between centers. Moreover, the number and the type of respiratory tract samples performed were not standardized over the study period, potentially hampering the isolation of Aspergillus spp. in patients having had limited microbiological investigations. Second, this was a retrospective study with possible associated errors in data abstraction. However, due to the relatively low frequency of IPA, prospective studies in the specific subgroup of ARDS patients would be hardly feasible due to the low rate of Aspergillus colonization [8]. Third, our patients were admitted over a 10-year period, with inherently associated selection bias related to variations in coding habits between years. Moreover, during this relatively long time period, exposure to Aspergillus spp. spores might have varied due to environmental factors. However, we found no association between the year of ICU admission and the risk of having one or more respiratory tract sample positive for Aspergillus spp. Fourth, several known prognostic factors for ARDS, including pulmonary artery pressure level or right ventricular dysfunction [31], were not available due to the retrospective nature of the study. Last, due to the limited number of patients having had a chest CT scan performed (n = 21/35), our study does not allow for drawing definite conclusions regarding the performance of chest CT scan in discriminating between putative aspergillosis and Aspergillus colonization in the context of ARDS.

Conclusions

We report a prevalence of 8% of Aspergillus-positive lower respiratory tract specimen culture and 4% of proven or putative IPA during ARDS. Immunocompromised ARDS patients were more likely to be categorized...
as having a putative or proven IPA, while non-immuno-compromised patients were more frequently classified as having *Aspergillus* respiratory tract colonization. Immunosuppression and pneumonia were associated with having at least one positive sample for *Aspergillus*. In this cohort of ARDS patients, having one or more positive sample for *Aspergillus* had no impact on outcome when classified as a mere respiratory tract colonization. In contrast, patients classified as having putative/proven IPA had a higher risk of in-ICU mortality, suggesting antifungal treatment should be assessed in this subgroup.

Abbreviations
ARDS: acute respiratory distress syndrome; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis.

Authors’ contributions
NDP, MD, JS, FF, FB, and AG collected the data; NDP, MD, and DC analyzed the data and wrote the manuscript; and KR, GC, FF, FB, AMD, and CB reviewed the manuscript. NDP is the guarantor of the article. All authors read and approved the final manuscript.

Author details
1 Groupe Henri Mondor-Albert Chenevier, Centre Hospitalier Universitaire Henri Mondor, DHU A-TV, Service de Réanimation Médicale, Assistance Publique-Hôpitaux de Paris, 94100 Créteil Cedex, France. 2 Groupe de Recherche CARMAS, Faculté de Médecine de Créteil, Université Paris Est Créteil, 94010 Créteil, France. 3 Centre Hospitalier Universitaire Henri Mondor, DHU A-TV, Antenne de Pneumatologie, Assistance Publique-Hôpitaux de Paris, 94010 Créteil, France. 4 Unité de Mycologie, Département de Biologie-Pathologie, Centre Hospitalier Universitaire Henri Mondor, DHU VIC, Assistance Publique-Hôpitaux de Paris, 94010 Créteil, France.

Competing interests
The authors declare they have no competing interests.

Ethic approval
This observational, non-interventional analysis of medical records was approved by the Institutional Review Board of the French Society for Respiratory Medicine. As per French law, no informed consent was required for this type of study.

Funding
This study did not receive funding from external or internal sources.

Received: 25 April 2016 Accepted: 5 June 2016 Published online: 13 June 2016

References
1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kaufman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.
2. Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis. 2014;27:174–83.
3. Dimopoulos G, Pignarelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother. 2003;15:71–5.
4. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeeken E, Peetermans WE, Van Wijngaarden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–5.
5. Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, Lagrou K, Wilmer A, Jorens P, Hermans G. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38:1761–8.
6. Tacccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, Paiva JA, Blasco-Navalpetro M, De Laere E, Dimopoulos G, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7.
7. Delucu C, Cottetreau A, Frealle E, Bienvenu AL, Dessein R, Jaraud S, Dumitrescu O, Le Marechal M, Wallet F, Friggeri A, et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study. Crit Care. 2015;19:421.
8. Bassetti M, Mikulski M, Repetto E, Bernardini C, Soro O, Molinari MP, Mussap M, Pallavicini FM, Viscoli C. Invasive pulmonary aspergillosis in intensive care units: is it a real problem? J Hosp Infect. 2009;74:186–7.
9. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, Irurtetayogena JR, Barcenilla F. Isolation of *Aspergillus* spp from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005;9:R191–9.
10. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004;59:251–7.
11. Vandewoude KH, Blot SJ, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D. Clinical relevance of *Aspergillus* isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.
12. ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporeota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526–33.
13. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A,Gattinoni L, van Haren F, Larsson A, McAuley DF, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.
14. Lugosi M, Alberti C, Zahar JR, Garroutte M, Lemiale V, Descorps-Desclere A, Ricard JD, Goldgran-Toledano D, Cohen Y, Schiewel C, et al. Aspergillosis in the lower respiratory tract of immunocompetent critically ill patients. J Infect. 2014;69:284–92.
15. de Hemptinne Q, Remmelink M, Brimouillé S, Salmon I, Vincent JL. ARDS: a clinicopathological confrontation. Chest. 2009;135:944–9.
16. Blot SJ, Tacccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusse-laers N, Dimopoulos G, Paiva JA, Misset B, Rello J, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:55–64.
17. Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect. 2010;16:1335–42.
18. Lortholary O, Meyohas MC, Dupont B, Cadranel J, Salmon-Ceron D, Peyramond D, Simonin D. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med. 1993;95:177–87.
19. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.
20. Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Antigas A, Teres D. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA. 1996;276:802–10.
21. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301–8.
22. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richesceur J, Nieszkowska A, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008;299:646–55.
23. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seighboyan JM, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107–16.
24. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159–68.
25. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brovier R, Esteban A, Gattinoni L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38:1573–82.
26. Azoulay E, Afessa B. Diagnostic criteria for invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:8–10.
27. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kressel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306:2594–605.
28. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.
29. Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis. 2014;59:569–77.
30. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spreet I, Verbeke E, Van Wijngaarden E. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27–34.
31. MekontsoDessap A, Boissier F, Charron C, Begot E, Repesse X, Lebras A, Brun-Buisson C, Vignon P, Vieillard-Baron A. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016;42:862–70.